Dopamine D2/3 receptor antagonism reduces activity-based anorexia

Anorexia nervosa (AN) is an eating disorder characterized by severe hypophagia and weight loss, and an intense fear of weight gain. Activity-based anorexia (ABA) refers to the weight loss, hypophagia and paradoxical hyperactivity that develops in rodents exposed to running wheels and restricted food access, and provides a model for aspects of AN. The atypical antipsychotic olanzapine was recently shown to reduce both AN symptoms and ABA. We examined which component of the complex pharmacological profile of olanzapine reduces ABA. Mice received 5-HT(2A/2C), 5-HT(3), dopamine D(1)-like, D(2), D(3) or D(2/3) antagonist treatment, and were assessed for food intake, body weight, wheel running and survival in ABA. D(2/3) receptor antagonists eticlopride and amisulpride reduced weight loss and hypophagia, and increased survival during ABA. Furthermore, amisulpride produced larger reductions in weight loss and hypophagia than olanzapine. Treatment with either D(3) receptor antagonist SB277011A or D(2) receptor antagonist L-741,626 also increased survival. All the other treatments either had no effect or worsened ABA. Overall, selective antagonism of D(2) and/or D(3) receptors robustly reduces ABA. Studies investigating the mechanisms by which D(2) and/or D(3) receptors regulate ABA, and the efficacy for D(2/3) and/or D(3) antagonists to treat AN, are warranted

Fundamental cosmological observations and data interpretation

ISBN 978364200791